TABLE 3.
Implementation of Hib vaccine in countries of the WHO Eastern Mediterranean Regiona
| Country | Yr of introduction | NIP | Formulation in 2019 | Schedule in 2019 | Coverage of Hib3 in 2019 (%) | Yr in which coverage reached ≥50% |
|---|---|---|---|---|---|---|
| Afghanistan | 2009 | Yes | DTwP/Hib/HepB | 6, 10, 14 wks | 66 | 2009 |
| Bahrain | 1998 | Yes | DTaP/Hib/HepB/IPV | 2, 4 mo | 99 | 1998 |
| DTwP/Hib/HepB | 6, 18 mo | |||||
| Hib (for SCD, asplenia, post-BMT, and post-cancer chemotherapy) | <5 yrs | |||||
| Djibouti | 2007 | Yes | DTwP/Hib/HepB | 6, 10, 14 wks | 85 | 2008 |
| Egypt | 2014 | Yes | DTwP/Hib/HepB | 2, 4, 6 mo | 95 | 2014 |
| Hib | 2, 4, 6 mo (previous adverse reaction after pertussis vaccination) | |||||
| Islamic Republic of Iran | 2014 | Yes | DTwP/Hib/HepB | 2, 4, 6 mo | 99 | 2015 |
| Hib | 2, 4, 6 mo (previous adverse reaction after pertussis vaccination) | |||||
| Iraq | 2012 | Yes | DTaP/Hib/HepB | 2, 4, 6 mo | 84 | 2013 |
| Jordan | 2001 | Yes | DTaP/Hib/HepB/IPV | 3, 4, 5 mo | 89 | 2001 |
| Hib | 3, 4, 5 mo | |||||
| Kuwait | 1998 | Yes | DTwP/Hib/HepB | 2, 4, 6, 18 mo | 91 | 1998 |
| Lebanon | 2003 | Yes | DTwP/Hib/HepB | 2, 4, 6, 18 mo | 85 | 2003 |
| Libya | 2007 | Yes | DTaP/Hib/HepB/IPV | 2, 4, 6 mo | 73 | 2007 |
| DTaP/Hib/IPV | 18 mo | |||||
| Morocco | 2007 | Yes | DTwP/Hib/HepB | 2, 3, 4 mo | 99 | 2007 |
| Oman | 2001 | Yes | DTaP/Hib/HepB/IPV | 2, 4 mo | 99 | 2002 |
| DTwP/Hib/HepB; Hib (immunocompromised) | 6 mo | |||||
| Pakistan | 2009 | Yes | DTwP/Hib/HepB | 6, 10, 14 wks | 75 | 2009 |
| Qatar | 1996 | Yes | DTaP/Hib/HepB/IPV | 2, 4 mo | 98 | 1997 |
| DTwP/Hib/HepB | 6 mo | |||||
| Saudi Arabia | 2002 | Yes | DTaP/Hib/HepB/IPV | 2, 4, 6 mo | 96 | 2002 |
| Somalia | 2013 | Yes | DTwP/Hib/HepB | 6, 10, 14 wks | 42 | |
| Sudan | 2008 | Yes | DTwP/Hib/HepB | 6, 10, 14 wks | 93 | 2008 |
| Syrian Arab Republic | 2001 | Yes | DTwP/Hib/HepB | 8, 16, 24 wks, 18 mo | 54 | 2001 (fell to <50% after 2012) |
| Tunisia | 2011 | Yes | DTwP/Hib/HepB | 2, 3, 6 mo | 92 | 2012 |
| United Arab Emirates | 1999 | Yes | DTaP/Hib/HepB/IPV | 2, 4 mo | 99 | 1999 |
| DTwP/Hib/HepB | 6 mo | |||||
| DTaP/Hib/IPV; Hib (high-risk groups) | 18 mo | |||||
| Yemen | 2005 | Yes | DTwP/Hib/HepB | 6, 10, 14 wks | 73 | 2006 |
a
Annual birth cohort, 17.3 million. Children aged <5 years, 85.3 million. Eighty-two percent of target population was immunized with three doses of Hib (Hib3) in 2019 (based on WHO-UNICEF estimates) (129). Abbreviations of vaccine antigens: D, diphtheria; T, tetanus; aP, acellular pertussis; wP, whole-cell pertussis; Hib, Haemophilus influenzae type b; HepB, hepatitis B virus surface antigen; IPV, inactivated poliovirus. NIP, national immunization program; SCD, sickle cell disease; BMT, bone marrow transplant.